PT3515894T - Compostos indazolo para utilização em lesões de tendões e/ou ligamentos - Google Patents

Compostos indazolo para utilização em lesões de tendões e/ou ligamentos

Info

Publication number
PT3515894T
PT3515894T PT177844040T PT17784404T PT3515894T PT 3515894 T PT3515894 T PT 3515894T PT 177844040 T PT177844040 T PT 177844040T PT 17784404 T PT17784404 T PT 17784404T PT 3515894 T PT3515894 T PT 3515894T
Authority
PT
Portugal
Prior art keywords
tendon
indazole compounds
ligament injuries
ligament
injuries
Prior art date
Application number
PT177844040T
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT3515894T publication Critical patent/PT3515894T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT177844040T 2016-09-23 2017-09-21 Compostos indazolo para utilização em lesões de tendões e/ou ligamentos PT3515894T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662398869P 2016-09-23 2016-09-23

Publications (1)

Publication Number Publication Date
PT3515894T true PT3515894T (pt) 2021-07-13

Family

ID=60084023

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177844040T PT3515894T (pt) 2016-09-23 2017-09-21 Compostos indazolo para utilização em lesões de tendões e/ou ligamentos

Country Status (38)

Country Link
US (1) US10112907B2 (pt)
EP (1) EP3515894B1 (pt)
JP (1) JP7007374B2 (pt)
KR (1) KR102490953B1 (pt)
CN (1) CN109715608B (pt)
AR (1) AR109688A1 (pt)
AU (1) AU2017332867B2 (pt)
BR (1) BR112019005578A2 (pt)
CA (1) CA3033249A1 (pt)
CL (1) CL2019000727A1 (pt)
CO (1) CO2019002616A2 (pt)
CR (1) CR20190145A (pt)
CU (1) CU24553B1 (pt)
CY (1) CY1124301T1 (pt)
DK (1) DK3515894T3 (pt)
DO (1) DOP2019000071A (pt)
EA (1) EA038510B1 (pt)
EC (1) ECSP19019589A (pt)
ES (1) ES2878585T3 (pt)
HR (1) HRP20211006T1 (pt)
HU (1) HUE054910T2 (pt)
IL (1) IL265066B (pt)
JO (1) JOP20190054B1 (pt)
LT (1) LT3515894T (pt)
MX (1) MX2019003362A (pt)
MY (1) MY196425A (pt)
PE (1) PE20190657A1 (pt)
PH (1) PH12019500327A1 (pt)
PL (1) PL3515894T3 (pt)
PT (1) PT3515894T (pt)
RS (1) RS62145B1 (pt)
RU (1) RU2749547C2 (pt)
SG (1) SG11201901146SA (pt)
SI (1) SI3515894T1 (pt)
TW (1) TWI651308B (pt)
UY (1) UY37412A (pt)
WO (1) WO2018055550A1 (pt)
ZA (1) ZA201900860B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190053A1 (ar) * 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
MX2021008303A (es) 2019-01-11 2021-10-13 Novartis Ag Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa.
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用lou064治療化膿性汗腺炎之方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0115102B1 (pt) * 2000-11-02 2013-11-26 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
JP2004518662A (ja) 2000-12-19 2004-06-24 スミスクライン ビーチャム パブリック リミテッド カンパニー Gsk−3阻害剤としてのピラゾロ[3,4−c]ピリジン
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE102004028862A1 (de) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
AU2008262038A1 (en) 2007-06-08 2008-12-18 AbbVie Deutschland GmbH & Co. KG 5-heteroaryl substituted indazoles as kinase inhibitors
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
JP2013542960A (ja) 2010-11-08 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド 脂肪酸シンターゼ阻害剤
BR112013021537B1 (pt) * 2011-02-24 2021-08-10 Nerviano Medical Sciences S.R.L. Derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
UA112028C2 (uk) * 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途

Also Published As

Publication number Publication date
CN109715608A (zh) 2019-05-03
ES2878585T3 (es) 2021-11-19
SG11201901146SA (en) 2019-04-29
EA201990766A1 (ru) 2019-08-30
PE20190657A1 (es) 2019-05-08
TWI651308B (zh) 2019-02-21
HUE054910T2 (hu) 2021-10-28
SI3515894T1 (sl) 2021-08-31
JOP20190054A1 (ar) 2019-03-21
AU2017332867A1 (en) 2019-03-07
KR20190053223A (ko) 2019-05-17
CU24553B1 (es) 2021-11-04
RU2019111883A3 (pt) 2020-11-05
EP3515894B1 (en) 2021-04-07
ECSP19019589A (es) 2019-03-29
CA3033249A1 (en) 2018-03-29
AU2017332867B2 (en) 2020-03-05
LT3515894T (lt) 2021-07-26
US10112907B2 (en) 2018-10-30
CR20190145A (es) 2019-06-03
CO2019002616A2 (es) 2019-06-11
JOP20190054B1 (ar) 2023-03-28
DK3515894T3 (da) 2021-07-05
JP2019529453A (ja) 2019-10-17
US20180086716A1 (en) 2018-03-29
CL2019000727A1 (es) 2019-05-17
HRP20211006T1 (hr) 2021-09-17
IL265066B (en) 2021-06-30
CY1124301T1 (el) 2022-07-22
JP7007374B2 (ja) 2022-01-24
CN109715608B (zh) 2022-08-05
RU2749547C2 (ru) 2021-06-15
PH12019500327A1 (en) 2019-11-11
CU20190028A7 (es) 2019-11-04
RS62145B1 (sr) 2021-08-31
WO2018055550A1 (en) 2018-03-29
KR102490953B1 (ko) 2023-01-19
EP3515894A1 (en) 2019-07-31
ZA201900860B (en) 2021-06-30
DOP2019000071A (es) 2019-05-15
MX2019003362A (es) 2019-07-04
UY37412A (es) 2018-04-30
RU2019111883A (ru) 2020-10-23
EA038510B1 (ru) 2021-09-08
PL3515894T3 (pl) 2021-10-25
AR109688A1 (es) 2019-01-16
MY196425A (en) 2023-04-10
BR112019005578A2 (pt) 2019-06-11
TW201815767A (zh) 2018-05-01

Similar Documents

Publication Publication Date Title
IL264763B (en) Aza-indazole compounds for use in tendon and/or ligament injuries
SI3075666T1 (sl) Naprava za držanje in uporabo naprave za uporabo v vesolju
IL251215A0 (en) Cannabinoid preparation and method for treating pain
IL272596A (en) Pridopidine for use in the treatment of ALS
HUE061764T2 (hu) Diaminopirimidin-P2X3 és P2X2/3 receptor modulátorok felhasználásra köhögés kezelésében
HK1252860A1 (zh) 用於在淋巴瘤或白血病中誘導淋巴細胞增多的針對人csf-1r的抗體
IL249400A0 (en) Orthopedic splints and methods for their production
IL271020A (en) Tinostemustine for the treatment of sarcoma
PL3362449T3 (pl) Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową
IL265066B (en) Indazole compounds for use in tendon and/or ligament injuries
GB201710793D0 (en) Apparatus and methods for thermally treating ligaments
HUE058749T2 (hu) Készítmények és módszerek homocisztinuria kezelésében történõ alkalmazásra
HK1256164A1 (zh) 用於治療神經膠質瘤的製劑
IL274822A (en) Substances for the treatment of depression and migraine
IL251949A0 (en) Small organic molecules for use in the treatment of neuro-inflammatory diseases
PL3135337T3 (pl) Urządzenie do relaksu i odnowy ciała
PL3166660T3 (pl) Substancje i sposoby do zastosowania w profilaktyce i/lub leczeniu choroby Huntingtona
GB201615844D0 (en) Agents for use in therapy
GB2541957B (en) Self-contained welfare unit for use in rail industry
PT3191112T (pt) Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura
ZA201807136B (en) Compositions for use in treating tendon degeneration
HK1252439A1 (zh) 用於處理人角蛋白材料的裝置
EP3592332C0 (fr) Nouvelle solution visco-élastique et son utilisation en rhumatologie
GB201718575D0 (en) Sink apparatus and use thereof
GB201518264D0 (en) Apparatus and methods for thermally treating ligaments